Precision radiation oncology in head and neck cancer: beyond physical precision - a narrative review

Abstract

Radiotherapy is an integral part of the management of head and neck cancers, both in radical and adjuvant settings. Traditionally, similar radiation dose and fractionation schedules have been used based on tumor stage with variable outcomes indicating “one size does not fit all”. In the era of precision medicine, though we have achieved physical precision with technological advancements, we have yet to attain biologic precision. In the current review, we have highlighted the different aspects of precision oncology such as hypoxia targeting, radiomics and radiogenomics, radiobiologic targeting, and big data. The review also discusses various potential therapeutic targets and approaches in head and neck cancer management that might help to increase radiosensitization, which in turn increase survival, and quality of life. This can be incorporated into the armamentarium of radiation oncology in all the phases of radiation planning, from diagnosis to treatment to the prognosis and management of long-term side effects. Biologic precision can be applied in the clinic to provide individualized, personalized treatment in the future.

Keywords

Head and neck cancer / precision oncology / radiation oncology / radiomics / big data

References

[1] Röntgen, Ueber eine neue art von Strahlen, Wurzburg, 1896. Available from: https://www.sothebys.com/buy/e1f1e6ca-ae21-4a47-b628-71aea6ab12e6/lots/feb988bf-f908-49c1-bfea-4687612640df [Last accessed on 28 Aug 2023]

[2] Gray LH,Ebert M,Scott OC.The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.Br J Radiol1953;26:638-48

[3] Vaupel P.Hypoxia in cancer: significance and impact on clinical outcome.Cancer Metastasis Rev2007;26:225-39

[4] Ejtehadifar M,Movassaghpour A.The effect of hypoxia on mesenchymal stem cell biology.Adv Pharm Bull2015;5:141-9 PMCID:PMC4517092

[5] Hawkins KE,McKay TR.The role of hypoxia in stem cell potency and differentiation.Regen Med2013;8:771-82

[6] Imanirad P.Hypoxia and HIFs in regulating the development of the hematopoietic system.Blood Cells Mol Dis2013;51:256-63 PMCID:PMC4604248

[7] Höckel M.Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.J Natl Cancer Inst2001;93:266-76

[8] Vaupel P,Okunieff P.Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.Cancer Res1989;49:6449-65

[9] Biologic basis of radiation oncology. 2015. Available from: https://clinicalgate.com/biologic-basis-of-radiation-oncology/ [Last accessed on 28 Aug 2023]

[10] Kabakov AE.Hypoxia-induced cancer cell responses driving radioresistance of hypoxic tumors: approaches to targeting and radiosensitizing.Cancers2021;13:1102 PMCID:PMC7961562

[11] Ameres SL.Diversifying microRNA sequence and function.Nat Rev Mol Cell Biol2013;14:475-88

[12] Chen D,Jin Y.MicroRNA deregulations in head and neck squamous cell carcinomas.J Oral Maxillofac Res2013;4:e2 PMCID:PMC3886106

[13] Ivan M.miR-210: fine-tuning the hypoxic response.Adv Exp Med Biol2014;772:205-27 PMCID:PMC4515752

[14] Toustrup K,Alsner J.Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy.Semin Radiat Oncol2012;22:119-27

[15] Toustrup K,Nordsmark M.Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer.Cancer Res2011;71:5923-31

[16] Eustace A,Span PN.A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.Clin Cancer Res2013;19:4879-88 PMCID:PMC3797516

[17] Kappler M,Kaune T.P4HA1: a single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients.Clin Transl Radiat Oncol2017;5:6-11 PMCID:PMC5833914

[18] Kaanders JH,van der Kogel AJ.Clinical studies of hypoxia modification in radiotherapy.Semin Radiat Oncol2004;14:233-40

[19] Vaupel P.Tumor microenvironmental physiology and its implications for radiation oncology.Semin Radiat Oncol2004;14:198-206

[20] Hoskin PJ,Phillips H.Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.Cancer2005;103:2287-97

[21] Kaanders JH,Marres HA.ARCON: experience in 215 patients with advanced head-and-neck cancer.Int J Radiat Oncol Biol Phys2002;52:769-78

[22] Nijkamp MM,Terhaard CH.Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.Eur J Cancer2013;49:3202-9

[23] Janssens GO,Terhaard CH.Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.Clin Cancer Res2014;20:1345-54

[24] Grégoire V,Kaanders J.OC-0278 Accelerated CH-RT with/without nimorazole for p16- HNSCC: the randomized DAHANCA 29-EORTC 1219 trial.Radiother Oncol2021;161:S187-8

[25] Semenza GL.Targeting HIF-1 for cancer therapy.Nat Rev Cancer2003;3:721-32

[26] Welsh S,Kirkpatrick L,Powis G.Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.Mol Cancer Ther2004;3:233-44

[27] Xia Y,Lee K.Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.Eur J Med Chem2012;49:24-40

[28] Aebersold DM,Beer KT.Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.Cancer Res2001;61:2911-6

[29] Adachi M,Dodge CT,Lai SY.Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma.Oral Oncol2012;48:1220-6 PMCID:PMC3734563

[30] Le QT.Clinical biomarkers for hypoxia targeting.Cancer Metastasis Rev2008;27:351-62 PMCID:PMC2835406

[31] Bennett MH,Smee R.Hyperbaric oxygenation for tumour sensitisation to radiotherapy.Cochrane Database Syst Rev2018;4:CD005007 PMCID:PMC6494427

[32] Rischin D,O’Sullivan B.Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.J Clin Oncol2010;28:2989-95

[33] Toustrup K,Lassen P,Alsner J.Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.Radiother Oncol2012;102:122-9

[34] Hoover AC,Anderson CM.Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trial.Head Neck2015;37:722-6 PMCID:PMC4285572

[35] Fisher R,Swanton C.Cancer heterogeneity: implications for targeted therapeutics.Br J Cancer2013;108:479-85 PMCID:PMC3593543

[36] Heppner GH.Tumor heterogeneity: biological implications and therapeutic consequences.Cancer Metastasis Rev1983;2:5-23

[37] Yokota J.Tumor progression and metastasis.Carcinogenesis2000;21:497-503

[38] Gerlinger M,Horswell S.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med2012;366:883-92 PMCID:PMC4878653

[39] Gillies RJ,Hricak H.Radiomics: images are more than pictures, they are data.Radiology2016;278:563-77 PMCID:PMC4734157

[40] Lambin P,Leijenaar R.Radiomics: extracting more information from medical images using advanced feature analysis.Eur J Cancer2012;48:441-6 PMCID:PMC4533986

[41] Yang X.Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review.J Biomed Biotechnol2011;2011:732848 PMCID:PMC3085501

[42] Basu S,Gatenby R,Torigian DA.Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders.Eur J Nucl Med Mol Imaging2011;38:987-91

[43] Aerts HJ,Leijenaar RT.Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.Nat Commun2014;5:4006

[44] Buch K,Li B,Qureshi MM.Using texture analysis to determine human papillomavirus status of oropharyngeal squamous cell carcinomas on CT.AJNR Am J Neuroradiol2015;36:1343-8 PMCID:PMC7965289

[45] Fujita A,Li B,Qureshi MM.Difference between HPV-positive and HPV-negative non-oropharyngeal head and neck cancer: texture analysis features on CT.J Comput Assist Tomogr2016;40:43-7

[46] Vallieres M,Sultanem K.FDG-PET image-derived features can determine hpv status in head-and-neck cancer.Int J Radiat Oncol Biol Phys2013;87:S467

[47] Horsman MR,Petersen JB,Overgaard J.Imaging hypoxia to improve radiotherapy outcome.Nat Rev Clin Oncol2012;9:674-87

[48] Servagi-Vernat S,Sterpin E.Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.Acta Oncol2015;54:1008-16

[49] Thorwarth D.Implementation of hypoxia imaging into treatment planning and delivery.Radiother Oncol2010;97:172-5

[50] Jeong J,Lee NY,Deasy JO.Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control.Radiother Oncol2014;111:340-7 PMCID:PMC4822492

[51] Leijenaar RT,Hoebers FJ.External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma.Acta Oncol2015;54:1423-9

[52] Hatt M,Vallières M.18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.J Nucl Med2015;56:38-44

[53] Zhang B,Ouyang F.Radiomic machine-learning classifiers for prognostic biomarkers of advanced nasopharyngeal carcinoma.Cancer Lett2017;403:21-7

[54] Parmar C,Rietveld D,Lambin P.Radiomic machine-learning classifiers for prognostic biomarkers of head and neck cancer.Front Oncol2015;5:272 PMCID:PMC4668290

[55] Reuz S,Ou D.A radiomic signature based on advanced tumor shape parameters (Spiculated-ness) to predict the outcome of locally advanced (LA) HNSCC patients.J Clin Oncol2016;34:11571

[56] Scalco E,Cattaneo GM,Rizzo G.Texture analysis for the assessment of structural changes in parotid glands induced by radiotherapy.Radiother Oncol2013;109:384-7

[57] Scalco E,Rizzo G.Texture analysis to assess structural modifications induced by radiotherapy.Annu Int Conf IEEE Eng Med Biol Soc2015;2015:5219-22

[58] Pota M,Sanguineti G.Early prediction of radiotherapy-induced parotid shrinkage and toxicity based on CT radiomics and fuzzy classification.Artif Intell Med2017;81:41-53

[59] van Dijk LV,Zhai TT.Delta-radiomics features during radiotherapy improve the prediction of late xerostomia.Sci Rep2019;9:12483 PMCID:PMC6713775

[60] Abdollahi H,Clark H.Radiomics-guided radiation therapy: opportunities and challenges.Phys Med Biol2022;67:12TR02

[61] Kann BH,Payabvash S.Multi-institutional validation of deep learning for pretreatment identification of extranodal extension in head and neck squamous cell carcinoma.J Clin Oncol2020;38:1304-11

[62] Zhou Z,Folkert M.Multifaceted radiomics for distant metastasis prediction in head & neck cancer.Phys Med Biol2020;65:155009

[63] Lu L,Jiang J.Robustness of radiomic features in [¹¹C]choline and [¹⁸F]FDG PET/CT imaging of nasopharyngeal carcinoma: impact of segmentation and discretization.Mol Imaging Biol2016;18:935-45

[64] Nikolov S,Zverovitch A.Clinically applicable segmentation of head and neck anatomy for radiotherapy: deep learning algorithm development and validation study.J Med Internet Res2021;23:e26151 PMCID:PMC8314151

[65] Bagher-Ebadian H,Liu C,Chetty IJ.On the impact of smoothing and noise on robustness of CT and CBCT radiomics features for patients with head and neck cancers.Med Phys2017;44:1755-70

[66] Park SY,Ye SJ,Park JM.Texture analysis on the fluence map to evaluate the degree of modulation for volumetric modulated arc therapy.Med Phys2014;41:111718

[67] Bogowicz M,Riesterer O.Targeting treatment resistance in head and neck squamous cell carcinoma - proof of concept for CT radiomics-based identification of resistant sub-volumes.Front Oncol2021;11:664304 PMCID:PMC8191457

[68] Guidi G,Vecchi C.A support vector machine tool for adaptive tomotherapy treatments: prediction of head and neck patients criticalities.Phys Med2015;31:442-51

[69] Lam LHT,Diep DTN.Molecular subtype classification of low-grade gliomas using magnetic resonance imaging-based radiomics and machine learning.NMR Biomed2022;35:e4792

[70] Kha QH,Hung TNK.Development and validation of an efficient MRI radiomics signature for improving the predictive performance of 1p/19q Co-deletion in lower-grade gliomas.Cancers2021;13:5398 PMCID:PMC8582370

[71] Caruso D,Zerunian M.Radiomics in oncology, part 1: technical principles and gastrointestinal application in CT and MRI.Cancers2021;13:2522 PMCID:PMC8196591

[72] Yip SS.Applications and limitations of radiomics.Phys Med Biol2016;61:R150-66 PMCID:PMC4927328

[73] Brouwer CL,Langendijk JA.Identifying patients who may benefit from adaptive radiotherapy: Does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help?.Radiother Oncol2015;115:285-94

[74] Laskar SG.HPV positive oropharyngeal cancer and treatment deintensification: how pertinent is it?.J Cancer Res Ther2015;11:6-9

[75] Scott JG,Schell MJ.A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.Lancet Oncol2017;18:202-11 PMCID:PMC7771305

[76] Torres-Roca JF,Zhao H.Prediction of radiation sensitivity using a gene expression classifier.Cancer Res2005;65:7169-76

[77] Eschrich SA,Zhang H.A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation.Int J Radiat Oncol Biol Phys2009;75:489-96 PMCID:PMC3038688

[78] Du Y,Grandis JR.Integration of molecular targeted therapy with radiation in head and neck cancer.Pharmacol Ther2014;142:88-98

[79] Gustafson DL,Merz AL.Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.Cancer Chemother Pharmacol2008;61:179-88

[80] Sano D,Valdecanas DR.Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro.Clin Cancer Res2011;17:1815-27 PMCID:PMC3074405

[81] Hsu HW,Hsueh CT.Combination antiangiogenic therapy and radiation in head and neck cancers.Oral Oncol2014;50:19-26

[82] Yadav A,Teknos TN.Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.Mol Cancer Ther2011;10:1241-51 PMCID:PMC3132282

[83] Bozec A,Toussan N,Etienne-Grimaldi MC.Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.Ann Oncol2009;20:1703-7

[84] de Bakker T,Descamps G.Restoring p53 function in head and neck squamous cell carcinoma to improve treatments.Front Oncol2021;11:799993 PMCID:PMC8770810

[85] Chen RC,Kavanagh BD.How will big data impact clinical decision making and precision medicine in radiation therapy?.Int J Radiat Oncol Biol Phys2016;95:880-4

[86] Jagsi R,Chen A.Considerations for observational research using large data sets in radiation oncology.Int J Radiat Oncol Biol Phys2014;90:11-24 PMCID:PMC4159773

[87] Robertson SP,Kiess AP.A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patients.Med Phys2015;42:4329-37

[88] Marungo F,Quon H.Creating a data science platform for developing complication risk models for personalized treatment planning in radiation oncology. In: 2015 48th Hawaii International Conference on System Sciences. Kauai, HI, USA; 5-8 January 2015; pp. 3132-40.

[89] Cavalieri S,Brakenhoff RH.Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: the big data to decide EU project.Head Neck2021;43:601-12 PMCID:PMC7820974

[90] Rosenstein BS,Efstathiou JA.How will big data improve clinical and basic research in radiation therapy?.Int J Radiat Oncol Biol Phys2016;95:895-904 PMCID:PMC4864183

[91] Willems SM,Feenstra KA.The potential use of big data in oncology.Oral Oncol2019;98:8-12

[92] Huser V.Impending challenges for the use of big data.Int J Radiat Oncol Biol Phys2016;95:890-4 PMCID:PMC4860172

[93] Jairam V.Strengths and limitations of large databases in lung cancer radiation oncology research.Transl Lung Cancer Res2019;8:S172-83 PMCID:PMC6795574

[94] Resteghini C,Borgonovi E.Big data in head and neck cancer.Curr Treat Options Oncol2018;19:62